Showing results (51-60 of 162) with videos related to

Sort By:
Pageof 17
Haematologica|February 19, 2011
Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemiaMichela Montagna, Marco Montillo, Maria A Avanzini, et al.
Haematologica|July 2, 2002
Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabineMarco Montillo, Anna Maria Cafro, Alessandra Tedeschi, et al.
Hematological Oncology|February 25, 2022
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statementS Ferrero, Massimo Gentile, Luca Laurenti, et al.
Hematological Oncology|March 5, 2022
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statementPier Luigi Zinzani, Maurizio Martelli, S Ferrero, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2007
High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical studyAlessandra Tedeschi, Marco Montillo, Elena Strocchi, et al.
Hemasphere|February 26, 2026
Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemiaRaúl Córdoba, Stephan Stilgenbauer, Paolo Ghia, et al.
Cancers|April 30, 2021
Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma CellsAlessandra Trojani, Barbara Di Camillo, Luca Emanuele Bossi, et al.
Cancers|March 25, 2022
From Biology to Treatment of Monoclonal Gammopathies of Neurological SignificanceAndrea Visentin, Stefano Pravato, Francesca Castellani, et al.
Hemasphere|March 2, 2022
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM TrialMichael Herold, Eva Hoster, Ann Janssens, et al.
Cancer Biomarkers : Section a of Disease Markers|February 19, 2010
ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemiaAlessandra Trojani, Marco Montillo, Michele Nichelatti, et al.
Pageof 17